Skip to main content
SCM Lifescience Co., Ltd. logo

SCM Lifescience Co., Ltd. — Investor Relations & Filings

Ticker · 298060 ISIN · KR7298060005 KO Manufacturing
Open in API
Filings indexed 418 across all filing types
Latest filing 2022-09-20 Major Shareholding Noti…
Country KR South Korea
Listing KO 298060

About SCM Lifescience Co., Ltd.

http://www.scmlifescience.com/en/

SCM Lifescience Co., Ltd. is a biotechnology company focused on developing high-purity, high-efficacy stem cell therapeutics for difficult-to-treat and incurable diseases. The company utilizes its proprietary source technology, the Subfractionation Culturing Method, to isolate and culture potent stem cells. Its pipeline consists of allogeneic stem cell therapies targeting immunological conditions, which are undergoing clinical trials. SCM Lifescience is also establishing mass production manufacturing processes using 3D bioreactor technology and expanding its research into induced pluripotent stem cells (iPSC) and tissue engineering. The company's business areas also include contract manufacturing (CMO), contract research, consulting, and cosmetics.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under Article 147 of the Capital Markets Act. It details changes in share ownership, specifically due to inheritance and changes in the representative reporter. This type of filing is classified as a Major Shareholding Notification (MRQ) as it tracks significant ownership thresholds and changes in control.
2022-09-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form in South Korea (often referred to as the '5% report' or 'insider ownership report') used to report changes in shareholdings by directors, executives, or major shareholders. Since it details the change in ownership due to inheritance (passing of the former representative), it falls under the category of Director's Dealing (DIRS), which covers insider share transactions and ownership changes.
2022-09-20 Korean
투자판단관련주요경영사항(중등증 이상의 급성 췌장염 환자 대상 SCM-AGH의 유효성 및 안전성을 평가하기 위한 제1/2a상 임상시험 결과)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from SCM Lifescience regarding the results of a Phase 1/2a clinical trial for a drug candidate (SCM-AGH). It follows the standard format for 'Major Management Matters' (주요경영사항) in the Korean stock market, which is used to disclose material events such as clinical trial results. Since it does not fit into specific categories like financial reports, dividends, or board changes, and is a formal regulatory disclosure of material information, it is classified as a Regulatory Filing (RNS).
2022-08-31 Korean
[기재정정]투자판단관련주요경영사항(중등증 이상의 급성 췌장염 환자 대상 SCM-AGH의 유효성 및 안전성을 평가하기 위한 제1/2a상 임상시험 결과)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from SCM Lifescience regarding the results of a Phase 1/2a clinical trial for a drug candidate (SCM-AGH). It is structured as a 'Major Management Matter' (투자판단 관련 주요경영사항) filing, which is a standard format for Korean public companies to disclose material events such as clinical trial results. Since it provides specific details on trial outcomes, safety, and efficacy rather than just announcing the existence of a report, it is classified as a Regulatory Filing (RNS) as it serves as a formal disclosure of material corporate information.
2022-08-31 Korean
반기보고서 (2022.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for SCM Lifescience, covering the period from 2022.01.01 to 2022.06.30. It contains detailed financial information, business operations, management discussions, and corporate governance details, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2022
2022-08-12 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share ownership of a specific individual (Son Byong Kwan) in SCM Lifescience Co., Ltd. following his appointment as an executive. This is a standard regulatory filing for insider shareholdings, which falls under the 'Director's Dealing' category.
2022-07-27 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.